ArticlePharmacoEconomics2007
Costs and benefits of direct-to-consumer advertising: the case of depression.
Article in PharmacoEconomics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Trial
- Attitudes, attributions, and usage patterns of primary care patients with regard to over-the-counter drugs-a survey in Germany.Wiener medizinische Wochenschrift (1946) · 2024Article
- Medicines Information and the Regulation of the Promotion of Pharmaceuticals.Science and engineering ethics · 2019Article
- Direct-to-consumer television advertising exposure, diagnosis with high cholesterol, and statin use.Journal of general internal medicine · 2013Article
- An academic-marketing collaborative to promote depression care: a tale of two cultures.Patient education and counseling · 2013Article
- The increasing frequency of mania and bipolar disorder: causes and potential negative impacts.The Journal of nervous and mental disease · 2012Review
- Health care providers and direct-to-consumer access and advertising of genetic testing in the United States.Genome medicine · 2011Article
- Effects of direct-to-consumer advertising and clinical guidelines on appropriate use of human papillomavirus DNA tests.Medical care · 2011Article
- Do antidepressant advertisements educate consumers and promote communication between patients with depression and their physicians?Patient education and counseling · 2010Article
- Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?Philosophy, ethics, and humanities in medicine : PEHM · 2008Article
- Does direct-to-consumer advertising of antidepressants lead to a net social benefit?PharmacoEconomics · 2008Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDirect-to-consumer advertising (DTCA) is legal in the US and New Zealand, but illegal in the rest of the world. Little or no research exists on the social welfare implications of DTCA.
aimTo quantify the total costs and benefits associated with both appropriate and inappropriate care due to DTCA, for the case of depression.
methodsA cost-benefit model was developed using parameter estimates from available survey, epidemiological and experimental data. The model estimates the total benefits and costs (year 2002 values) of new appropriate and inappropriate care stimulated by DTCA for depression. Uncertainty in model parameters is addressed with sensitivity analyses.
resultsThis study provides evidence that 94% of new antidepressant use due to DTCA is from non-depressed individuals. However, the average health benefit to each new depressed user is 63-fold greater than the cost per treatment, creating a positive overall social welfare effect; a net benefit of >72 million US dollars.
conclusionThis analysis suggests that DTCA may lead to antidepressant treatment in 15-fold as many non-depressed people as depressed people. However, the costs of treating non-depressed people may be vastly outweighed by the much larger benefit accruing to treated depressed individuals. The cost-benefit ratio can be improved through better targeting of advertisements and higher quality treatment of depression.
Indexed as
Identifiers
17523755What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.